Camrelizumab combined with apatinib and albumin-bound paclitaxel followed by camrelizumab plus apatinib as first-line therapy for unresectable or metastatic pancreatic cancer.

被引：0
|
作者：
Shen, Bo [1 ]
Wu, Yuan [1 ]
机构：
[1] Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Canc Hosp, Internal Med Oncol, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
703
引用
收藏
页码：703 / 703
页数：1
相关论文
共 50 条
  • [21] BUDGET IMPACT OF ALBUMIN-BOUND PACLITAXEL plus GEMCITABINE IN THE TREATMENT OF METASTATIC PANCREATIC CANCER
    Binder, G.
    Whiting, S.
    Milentijevic, D.
    Penenberg, D.
    Wei, X.
    Kayitalire, L.
    Renschler, M. F.
    VALUE IN HEALTH, 2014, 17 (03) : A74 - A74
  • [22] Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
    Zhao, Y.
    Liu, J.
    Li, X.
    Li, Y.
    Pu, H.
    Wang, X.
    Yang, M.
    Bai, S.
    Guo, L.
    Zhao, L.
    Zhang, M.
    Zhao, H.
    Xu, S.
    Wang, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1674 - S1674
  • [23] A multicenter phase I/II trial of induction chemotherapy followed by camrelizumab, apatinib, plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer
    Zhou, Chengzhi
    Liu, Ming
    Qiu, Guihuan
    Xie, Xiaohong
    Lin, Xinqing
    Guan, Wenhui
    Xie, Zhanhong
    Zhang, Jiexia
    Qin, Yinyin
    Du, Haijian
    Chen, Xin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, single-arm trial
    Liu, Ming
    Qiu, Guihuan
    Guan, Wenhui
    Xie, Xiaohong
    Lin, Xinqing
    Xie, Zhanhong
    Zhang, Jiexia
    Qin, Yinyin
    Du, Haijian
    Chen, Xin
    Deng, Yu
    Li, Shiyue
    Zhong, Nanshan
    Zhou, Chengzhi
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2025, 10 (01)
  • [25] Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer
    Xuetong Rong
    Haiyi Liu
    Hongmei Yu
    Jian Zhao
    Jie Wang
    Yusheng Wang
    Investigational New Drugs, 2022, 40 : 340 - 348
  • [26] Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma
    Shi, Yan
    Qin, Rui
    Wang, Zhi-Kuan
    Dai, Guang-Hai
    ONCOTARGETS AND THERAPY, 2013, 6 : 585 - 591
  • [27] Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer
    Rong, Xuetong
    Liu, Haiyi
    Yu, Hongmei
    Zhao, Jian
    Wang, Jie
    Wang, Yusheng
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (02) : 340 - 348
  • [28] Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients
    Ma, Ning
    Qiao, Hui
    Tao, Hanchuan
    Gan, Xinli
    Shan, Zhili
    Chen, Xiaomin
    Zhou, Xiaojun
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2022, 46 (07)
  • [29] Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma
    Zhang, Bo
    Qi, Ling
    Wang, Xi
    Xu, Jianping
    Liu, Yun
    Mu, Lan
    Wang, Xingyuan
    Bai, Lidan
    Huang, Jing
    CANCER COMMUNICATIONS, 2020, 40 (12) : 711 - 720
  • [30] Preliminary data of a phase Ib/II trial evaluating the efficacy and safety of adebrelimab, camrelizumab plus apatinib as first-line therapy in patients with advanced hepatocellular carcinoma
    Long, Yin
    Yang, Qiong
    Huang, Ziqi
    He, Xiaodong
    Huang, Jue
    Liao, Jianguo
    Chen, Yajin
    Hu, Hai
    Zhang, Lei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345